Hopp acquires LTS shares from Novartis & BWK / LTS: market leader in transdermal patches completely acquired by dievini Hopp

Andernach (ots) - The supervisory board ("Aufsichtsrat") and
management board ("Vorstand") of LTS have concluded the assessment of
strategic options for the future development of the LTS group. LTS
developed innovative, value oriented growth strategies identifying
also the prerequisites for the successful strategy implementation.
Meanwhile, LTS´s major shareholders evaluated possible changes in
ownership.

Upon the conclusion of the assessment the three main shareholders
have agreed a transaction amongst themselves.

The dievini Hopp Biotech Holding GmbH & Co KG Walldorf/ Germany,
the Novartis Holding AG Basel/Switzerland and BWK GmbH
Stuttgart/Germany announce that dievini will acquire all shares of
the two other LTS main shareholders. Novartis will divest its 43%
stake in LTS Lohmann Therapie-Systeme AG (LTS), BWK will divest its
24% stake to dievini Hopp. Small LTS shareholders will also receive
an equal offer from dievini Hopp. The transaction, which requires
regulatory approvals and is subject to other customary conditions, is
expected to close this year.

The supervisory board and management board of LTS welcome the
agreement of its shareholders. dievini´s continued and strategic
engagement enables LTS to realize the identified attractive growth
options with its own means available. The agreement provides for the
prerequisites to develop LTS sustainably and independently as the
technologically leading global pharmaceutical company for transdermal
technologies.

LTS supervisory board chairman Prof. Loos: "The supervisory board
of LTS welcomes the strategic decision of LTS´s main shareholders as
it anticipates the successful, sustainable development of LTS in the
next LTS development phase. "

Christof Hettich Managing Director of dievini Hopp: " As a
shareholder since many years we know and appreciate LTS. We are
delighted to partake also in the future in the successful work of LTS
in an even closer fashion. As the global market leader for
transdermal pharmaceutical solutions LTS offers significant potential
for innovation to the benefit of patients and medical therapy. "

About LTS:

LTS is the global market leader in the development and
manufacturing of innovative transdermal systems LTS TTS and oral thin
films LTS OTF. Founded in 1984, LTS is a German based pharmaceutical
company with global presence and operations in both in Germany and
the USA, employing about 1500 and a yearly turnover exceeding EUR 300
mio.

Contacts
dievini Hopp BioTech holding GmbH & Co KG
Tel. + 49 (0)621 4256 208

LTS AG
Tel.: + 49 (0)2632 990
Mail: info@ltslohmann.de